Components:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 11.05.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
constipation
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.The Atropine (Redotex)® (Atropine (Redotex)) Auto-injector is indicated for the treatment of poisoning by susceptible organophosphorous nerve agents having cholinesterase activity as well as organophosphorous or carbamate insecticides. The Atropine (Redotex) (Atropine (Redotex)) auto-injector should be used by persons who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication. Pralidoxime chloride may serve as an important adjunct to Atropine (Redotex) therapy.
The Atropine (Redotex)® (Atropine (Redotex)) is intended as an initial treatment of the muscarinic symptoms of insecticide or nerve agent poisonings (generally breathing difficulties due to increased secretions); definitive medical care should be sought immediately. The Atropine (Redotex)® (Atropine (Redotex)) Auto-injector should be administered as soon as symptoms of organophosphorous or carbamate poisoning appear (usually tearing, excessive oral secretions, wheezing, muscle fasciculations, etc.) In moderate to severe poisoning, the administration of more than one Atropine (Redotex)® (Atropine (Redotex)) may be required until atropinization is achieved (flushing, mydriasis, tachycardia, dryness of the mouth and nose). In severe poisonings, it may also be desirable to concurrently administer an anticonvulsant if seizure is suspected in the unconscious individual since the classic tonic-clonic jerking may not be apparent due to the effects of the poison. In poisonings due to organophosphorous nerve agents and insecticides it may also be helpful to concurrently administer a cholinesterase reactivator such as pralidoxime chloride.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Oral
Obesity
Adult: As extended-release cap: 20-50 mg once daily after breakfast for up to 4 wk.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Diazepam (Redotex) Rectal Gel is a gel formulation of Diazepam (Redotex) intended for rectal administration in the management of selected, refractory, patients with epilepsy, on stable regimens of AEDs, who require intermittent use of Diazepam (Redotex) to control bouts of increased seizure activity.
Evidence to support the use of Diazepam (Redotex) Rectal Gel was adduced in two controlled trials that enrolled patients with partial onset or generalized convulsive seizures who were identified jointly by their caregivers and physicians as suffering intermittent and periodic episodes of markedly increased seizure activity, sometimes heralded by nonconvulsive symptoms, that for the individual patient were characteristic and were deemed by the prescriber to be of a kind for which a benzodiazepine would ordinarily be administered acutely. Although these clusters or bouts of seizures differed among patients, for any individual patient the clusters of seizure activity were not only stereotypic but were judged by those conducting and participating in these studies to be distinguishable from other seizures suffered by that patient. The conclusion that a patient experienced such unique episodes of seizure activity was based on historical information.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Thyroid hormone drugs are indicated:
As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter.
As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.
Liothyronine (Redotex) (Liothyronine (Redotex) sodium) Tablets can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.
Atropine (Redotex) produces many effects in the body such as reducing muscle spasms and fluid secretions.
Atropine (Redotex) is used to help reduce saliva, mucus, or other secretions in your airway during a surgery. Atropine (Redotex) is also used to treat spasms in the stomach, intestines, bladder, or other organs.
Atropine (Redotex) is sometimes used as an antidote to treat certain types of poisoning.
Atropine (Redotex) may also be used for purposes not listed in this medication guide.
Diazepam (Redotex) is a benzodiazepine (ben-zoe-dye-AZE-eh-peen). Diazepam (Redotex) affects chemicals in the brain that may be unbalanced in people with certain conditions.
Diazepam (Redotex) injection is used to treat anxiety disorders, alcohol withdrawal symptoms, or muscle spasms. Diazepam (Redotex) injection is also used to treat a seizure emergency called status epilepticus.
Diazepam (Redotex) injection is sometimes used as a sedative to help you relax before having surgery or other medical procedure.
Diazepam (Redotex) may also be used for purposes not listed in this medication guide.
Liothyronine (Redotex) is a man-made form of a hormone that is normally produced by your thyroid gland to regulate the body's energy and metabolism. Liothyronine (Redotex) is given when the thyroid does not produce enough of this hormone on its own.
Liothyronine (Redotex) treats hypothyroidism (low thyroid hormone). Liothyronine (Redotex) is also used to treat or prevent goiter (enlarged thyroid gland), and is also given as part of a medical tests for thyroid disorders.
Liothyronine (Redotex) should not be used to treat obesity or weight problems.
Liothyronine (Redotex) may also be used for purposes not listed in this medication guide.
CAUTION! PRIMARY PROTECTION AGAINST EXPOSURE TO CHEMICAL NERVE AGENT AND INSECTICIDE POISONING IS THE WEARING OF PROTECTIVE GARMENTS INCLUDING MASKS, DESIGNED SPECIFICALLY FOR THIS USE.
INDIVIDUALS SHOULD NOT RELY SOLELY UPON THE AVAILABILITY OF ANTIDOTES SUCH AS Atropine (Redotex) AND PRALIDOXIME TO PROVIDE COMPLETE PROTECTION FROM CHEMICAL NERVE AGENT AND INSECTICIDE POISONING.
Immediate evacuation from the contaminated environment is essential. Decontamination of the poisoned individual should occur as soon as possible.
The Atropine (Redotex)® (Atropine (Redotex)) Auto-injector is indicated for the treatment of poisoning by susceptible organophosphorous nerve agents having cholinesterase activity as well as organophosphorous or carbamate insecticides. The Atropine (Redotex)® (Atropine (Redotex)) auto-injector should be used by persons who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication. Pralidoxime chloride may serve as an important adjunct to Atropine (Redotex) therapy.
The Atropine (Redotex)® (Atropine (Redotex)) is intended as an initial treatment of the muscarinic symptoms of insecticide or nerve agent poisonings (generally breathing difficulties due to increased secretions); definitive medical care should be sought immediately. The Atropine (Redotex)® (Atropine (Redotex)) Auto-injector should be administered as soon as symptoms of organophosphorous or carbamate poisoning appear (usually tearing, excessive oral secretions, wheezing, muscle fasciculations, etc.) In moderate to severe poisoning, the administration of more than one Atropine (Redotex)® (Atropine (Redotex)) may be required until atropinization is achieved (flushing, mydriasis, tachycardia, dryness of the mouth and nose). In severe poisonings, it may also be desirable to concurrently administer an anticonvulsant if seizure is suspected in the unconscious individual since the classic tonic-clonic jerking may not be apparent due to the effects of the poison. In poisonings due to organophosphorous nerve agents and insecticides it may also be helpful to concurrently administer a cholinesterase reactivator such as pralidoxime chloride.
It is recommended that three (3) Atropine (Redotex)® (Atropine (Redotex)) auto-injectors be available for use in each person at risk for nerve agent or organophosphate insecticide poisoning; one (1) for mild symptoms plus two (2) more for severe symptoms as described below. No more than three (3) Atropine (Redotex)® (Atropine (Redotex)) injections should be used unless the patient is under the supervision of a trained medical provider. Different dose strengths of the Atropine (Redotex)® (Atropine (Redotex)) are available depending on the recipient's age and weight.
- Adults and children weighing over 90 lbs (generally over 10 years of age)..............Atropine (Redotex)® (Atropine (Redotex)) 2 mg (green)
- Children weighing 40 lbs to 90 lbs (generally 4 to 10 years of age)..............Atropine (Redotex)® (Atropine (Redotex)) 1 mg (dark red)
- Children weighing 15 lbs to 40 lbs (generally 6 months to 4 years of age)..............Atropine (Redotex)® (Atropine (Redotex)) 0.5 mg (blue)
NOTE: Children weighing under 15 lbs (generally younger than 6 months old) should ordinarily not be treated with the Atropine (Redotex)® auto-injector. Atropine (Redotex) doses for these children should be individualized at doses of 0.05 mg/kg.
Treatment of MILD SYMPTOMS
One (1) Atropine (Redotex)® (Atropine (Redotex)) is recommended if two or more MILD symptoms of nerve agent (nerve gas) or insecticide exposure appear in situations where exposure is known or suspected.
Two (2) additional Atropine (Redotex)® (Atropine (Redotex)) injections given in rapid succession are recommended 10 minutes after receiving the first Atropine (Redotex)® (Atropine (Redotex)) injection if the victim develops any of the SEVERE symptoms listed below. If possible, a person other than the victim should administer the second and third Atropine (Redotex)® (Atropine (Redotex)) injections.
Treatment of SEVERE SYMPTOMS:
If a victim is encountered who is either unconscious or has any of the SEVERE symptoms listed below, immediately administer three (3) Atropine (Redotex)® (Atropine (Redotex)) injections into the victim's mid-lateral thigh in rapid succession using the appropriate weight-based Atropine (Redotex)® (Atropine (Redotex)) dose.
MILD SYMPTOMS of nerve agent or insecticide exposure include the following:
-Blurred vision, miosis
-Excessive unexplained teary eyes
-Excessive unexplained runny nose
-Increased salivation such as sudden unexplained excessive drooling
-Chest tightness or difficulty breathing
-Tremors throughout the body or muscular twitching
-Nausea and/or vomiting
-Unexplained wheezing or coughing
-Acute onset of stomach cramps
-Tachycardia or bradycardia
SEVERE SYMPTOMS of exposure to nerve agent or insecticides include the following:
-Strange or confused behavior
-Severe difficulty breathing or severe secretions from your lungs/airway
-Severe muscular twitching and general weakness
-Involuntary urination and defecation (feces)
-Convulsions
-Unconsciousness
All victims should be evacuated immediately from the contaminated environment. Medical help should be sought immediately. Protective masks and clothing should be used when available. Decontamination procedures should be undertaken as soon as possible. If dermal exposure has occurred, clothing should be removed and the hair and skin washed thoroughly with sodium bicarbonate or alcohol as soon as possible.
Emergency care of the severely poisoned individual should include removal of oral and bronchial secretions, maintenance of a patent airway, supplemental oxygen and, if necessary, artificial ventilation. In general, Atropine (Redotex) should not be used until cyanosis has been overcome since Atropine (Redotex) may produce ventricular fibrillation and possible seizures in the presence of hypoxia.
Pralidoxime (if used) is most effective if administered immediately or soon after the poisoning. Generally, little is accomplished if pralidoxime is given more than 36 hours after termination of exposure unless the poison is known to age slowly or re-exposure is possible, such as in delayed continuing gastrointestinal absorption of ingested poisons. Fatal relapses, thought to be due to delayed absorption, have been reported after initial improvement. Continued administration for several days may be useful in such patients.
Close supervision of all moderately to severely poisoned patients is indicated for at least 48 to 72 hours.
An anticonvulsant such as diazepam may be administered to treat convulsions if suspected in the unconscious individual. The effects of nerve agents and some insecticides can mask the motor signs of a seizure.
IMPORTANT: PHYSICIANS AND/OR OTHER MEDICAL PERSONNEL ASSISTING EVACUATED VICTIMS OF NERVE AGENTS AND INSECTICIDE POISONING SHOULD AVOID EXPOSING THEMSELVES TO CONTAMINATION BY THE VICTIM'S CLOTHING. AGGRESSIVE AND SAFE DECONTAMINATION IS STRONGLY SUGGESTED.
Instructions for administering Atropine (Redotex)® (Atropine (Redotex)) (please refer to the illustrated Self Aid and Caregiver Directions for Use elsewhere):
Warning: Giving additional Atropine (Redotex)® (Atropine (Redotex)) injections by mistake in the absence of actual nerve agent or insecticide poisoning may cause an overdose of Atropine (Redotex) which could result in temporary incapacitation (inability to walk properly, see clearly or think clearly for several or more hours). Patients with cardiac disease may be at risk for serious adverse events, including death.
How supplied
The Atropine (Redotex)® (Atropine (Redotex)) is supplied in three strengths. The Atropine (Redotex)® 0.5 mg provides Atropine (Redotex) Injection (Atropine (Redotex), 0.42 mg/0.7 ml), Atropine (Redotex)® 1 mg provides Atropine (Redotex) Injection (Atropine (Redotex), 0.84 mg/0.7 ml), and Atropine (Redotex)® 2 mg provides Atropine (Redotex) Injection (Atropine (Redotex), 1.67 mg/0.7 ml) in sterile solution for intramuscular injection. The Atropine (Redotex)® (Atropine (Redotex)) is a self-contained unit designed for self or caregiver administration.
Store at 25° C (77° F); excursions permitted to 15–30° C (59–86° F)
Keep from freezing. Protect from light.
Manufactured by: MERIDIAN MEDICAL TECHNOLOGIES, INC., 10240 Old Columbia Road, COLUMBIA, MD 21046. FDA Rev date: 9/17/2004
Oral
Obesity
Adult: As extended-release cap: 20-50 mg once daily after breakfast for up to 4 wk.
This section is intended primarily for the prescriber; however, the prescriber should also be aware of the dosing information and directions for use provided in the patient package insert.
A decision to prescribe Diazepam (Redotex) rectal gel involves more than the diagnosis and the selection of the correct dose for the patient.
First, the prescriber must be convinced from historical reports and/or personal observations that the patient exhibits the characteristic identifiable seizure cluster that can be distinguished from the patient's usual seizure activity by the caregiver who will be responsible for administering Diazepam (Redotex) rectal gel.
Second, because Diazepam (Redotex) rectal gel is only intended for adjunctive use, the prescriber must ensure that the patient is receiving an optimal regimen of standard anti-epileptic drug treatment and is, nevertheless, continuing to experience these characteristic episodes.
Third, because a non-health professional will be obliged to identify episodes suitable for treatment, make the decision to administer treatment upon that identification, administer the drug, monitor the patient, and assess the adequacy of the response to treatment, a major component of the prescribing process involves the necessary instruction of this individual.
Fourth, the prescriber and caregiver must have a common understanding of what is and is not an episode of seizures that is appropriate for treatment, the timing of administration in relation to the onset of the episode, the mechanics of administering the drug, how and what to observe following administration, and what would constitute an outcome requiring immediate and direct medical attention.
Calculating Prescribed Dose
The Diazepam (Redotex) rectal gel dose should be individualized for maximum beneficial effect. The recommended dose of Diazepam (Redotex) rectal gel is 0.2-0.5 mg/kg depending on age. See the dosing table for specific recommendations.
How supplied
Diazepam (Redotex) Rectal Gel rectal delivery system is a non-sterile, prefilled, unit dose, rectal delivery system. The rectal delivery system includes a plastic applicator with a flexible, molded tip available in two lengths, designated for convenience as 10 mg delivery system and 20 mg delivery system. The available doses from 20 mg delivery system are 12.5 mg, 15 mg, 17.5 mg, and 20 mg. The available doses from 10 mg delivery system are 5 mg, 7.5 mg and 10 mg. The Diazepam (Redotex) Rectal Gel delivery system is available in the following three presentations:
Diazepam (Redotex) Rectal Gel | Rectal Tip Size | NDC |
2.5 mg Twin Pack | 4.4 cm | NDC 0093-6137-32 |
Diazepam (Redotex) Rectal Gel | Rectal Tip Size | NDC |
10 mg Delivery System Twin Pack | 4.4 cm | NDC 0093-6138-32 |
20 mg Delivery System Twin Pack | 6.0 cm | NDC 0093-6139-32 |
Each twin pack contains two Diazepam (Redotex) Rectal Gel delivery systems, two packets of lubricating jelly, and administration and disposal Instructions available on the bottom of the package. Diazepam (Redotex) Rectal Gel is also packed with Instructions for Caregivers upon receipt from pharmacy.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).
Diazepam (Redotex) Rectal Gel 10 mg delivery system and 20 mg delivery system
Distributed by: TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454. Manufactured By: DPT Laboratories, LTD., San Antonio, TX 78215, 9435000. Revised: Feb 2015
Adults
Myxedema coma is usually precipitated in the hypothyroid patient of long standing by intercurrent illness or drugs such as sedatives and anesthetics and should be considered a medical emergency. Therapy should be directed at the correction of electrolyte disturbances, possible infection, or other intercurrent illness in addition to the administration of intravenous Liothyronine (Redotex) (T3). Simultaneous glucocorticosteroids are required.
Liothyronine (Redotex) (Liothyronine (Redotex) sodium injection) (T3) is for intravenous administration only. It should not be given intramuscularly or subcutaneously.
-
Prompt administration of an adequate dose of intravenous Liothyronine (Redotex) (T3) is important in determining clinical outcome.
-
Initial and subsequent doses of Liothyronine (Redotex) should be based on continuous monitoring of the patient's clinical status and response to therapy.
-
Liothyronine (Redotex) doses should normally be administered at least four hours–and not more than 12 hours–apart.
-
Administration of at least 65 mcg/day of intravenous Liothyronine (Redotex) (T3) in the initial days of therapy was associated with lower mortality.
-
There is limited clinical experience with intravenous Liothyronine (Redotex) (T3) at total daily doses exceeding 100 mcg/day.
No controlled clinical studies have been done with Liothyronine (Redotex). The following dosing guidelines have been derived from data analysis of myxedema coma/precoma case reports collected by SmithKline Beecham Pharmaceuticals since 1963 and from scientific literature since 1956.
An initial intravenous Liothyronine (Redotex) dose ranging from 25 mcg to 50 mcg is recommended in the emergency treatment of myxedema coma/precoma in adults. In patients with known or suspected cardiovascular disease, an initial dose of 10 mcg to 20 mcg is suggested. However, both the initial dose and subsequent doses should be determined on the basis of continuous monitoring of the patient's clinical condition and response to Liothyronine (Redotex) therapy. Normally at least four hours should be allowed between doses to adequately assess therapeutic response and no more than 12 hours should elapse between doses to avoid fluctuations in hormone levels. Caution should be exercised in adjusting the dose due to the potential of large changes to precipitate adverse cardiovascular events. Review of the myxedema case reports indicates decreased mortality in patients receiving at least 65 mcg/day in the initial days of treatment. However, there is limited clinical experience at total daily doses above 100 mcg. See PRECAUTIONS–Drug Interactions for potential interactions between thyroid hormones and digitalis and vasopressors.
Pediatric Use
There is limited experience with Liothyronine (Redotex) in the pediatric population. Safety and effectiveness in pediatric patients have not been established.
Switching to
Oral Therapy
Oral therapy should be resumed as soon as the clinical situation has been stabilized and the patient is able to take oral medication. When switching a patient to Liothyronine (Redotex) sodium tablets from Liothyronine (Redotex), discontinue Liothyronine (Redotex), initiate oral therapy at a low dosage, and increase gradually according to the patient's response.
If L-thyroxine rather than Liothyronine (Redotex) sodium is used in initiating oral therapy, the physician should bear in mind that there is a delay of several days in the onset of L-thyroxine activity and that intravenous therapy should be discontinued gradually.
See also:
What is the most important information I should know about Atropine (Redotex)?
Known hypersensitivity to Atropine (Redotex) or other anticholinergic agents.
Severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; gastrointestinal obstruction eg, pyloroduodenal stenosis, achalasia, cardiospasm, paralytic ileus, intestinal atony; closed-angle glaucoma; obstructive uropathy eg, bladder neck obstruction caused by prostatic hypertrophy; myasthenia gravis; tachycardia secondary to cardiac insufficiency or thyrotoxicosis; acute hemorrhage with unstable cardiovascular status; febrile patients or patients exposed to elevated ambient temperature due to risk of provoking hyperpyrexia and heat prostration; prostatic enlargement; pregnancy-induced hypertension.
Patients treated with MAOI or stopped MAOI within the last 2 wk; moderate or severe hypertension; pulmonary hypertension; structural cardiac abnormalities or advanced arteriosclerosis; adrenal tumour; hyperthyroidism or hyperexcitability; coronary thrombosis; closed-angle glaucoma; pregnancy.
See also:
What is the most important information I should know about Diazepam (Redotex)?
You should not use this medication if you are allergic to Diazepam (Redotex) or similar medicines (Ativan, Klonopin, Restoril, Xanax, and others), or if you have myasthenia gravis, severe liver disease, narrow-angle glaucoma, a severe breathing problem, or sleep apnea.
Do not use Diazepam (Redotex) if you are pregnant. It could harm the unborn baby.
Do not start or stop taking Diazepam (Redotex) during pregnancy without your doctor's advice. Diazepam (Redotex) may cause harm to an unborn baby, but having a seizure during pregnancy could harm both the mother and the baby. Tell your doctor right away if you become pregnant while taking Diazepam (Redotex) for seizures.
Before you take Diazepam (Redotex), tell your doctor if you have glaucoma, asthma or other breathing problems, kidney or liver disease, seizures, or a history of drug or alcohol addiction, mental illness, depression, or suicidal thoughts.
Do not drink alcohol while taking Diazepam (Redotex). This medication can increase the effects of alcohol.
Never take more of this medication than your doctor has prescribed. An overdose of Diazepam (Redotex) can be fatal.
Diazepam (Redotex) may be habit forming. Never share Diazepam (Redotex) with another person, especially someone with a history of drug abuse or addiction.
See also:
What is the most important information I should know about Liothyronine (Redotex)?
Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone.
Warnings
Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
The use of thyroid hormones in the therapy of obesity, alone or combined with other drugs, is unjustified and has been shown to be ineffective. Neither is their use justified for the treatment of male or female infertility unless this condition is accompanied by hypothyroidism.
Thyroid hormones should be used with great caution in a number of circumstances where the integrity of the cardiovascular system, particularly the coronary arteries, is suspected. These include patients with angina pectoris or the elderly, in whom there is a greater likelihood of occult cardiac disease. In these patients, Liothyronine (Redotex) sodium therapy should be initiated with low doses, with due consideration for its relatively rapid onset of action. Starting dosage of Liothyronine (Redotex) Sodium Tablets, USP is 5 mcg daily, and should be increased by no more than 5 mcg increments at 2-week intervals. When, in such patients, a euthyroid state can only be reached at the expense of an aggravation of the cardiovascular disease, thyroid hormone dosage should be reduced.
Morphologic hypogonadism and nephrosis should be ruled out before the drug is administered. If hypopituitarism is present, the adrenal deficiency must be corrected prior to starting the drug.
Myxedematous patients are very sensitive to thyroid; dosage should be started at a very low level and increased gradually.
Severe and prolonged hypothyroidism can lead to a decreased level of adrenocortical activity commensurate with the lowered metabolic state. When thyroid-replacement therapy is administered, the metabolism increases at a greater rate than adrenocortical activity. This can precipitate adrenocortical insufficiency. Therefore, in severe and prolonged hypothyroidism, supplemental adrenocortical steroids may be necessary. In rare instances the administration of thyroid hormone may precipitate a hyperthyroid state or may aggravate existing hyperthyroidism.
Use Atropine (Redotex) drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Atropine (Redotex) drops. Talk to your pharmacist if you have questions about this information.
- To use Atropine (Redotex) drops in the eye, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eyelid for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean, dry tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
- To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.
- If you miss a dose of Atropine (Redotex) drops, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Atropine (Redotex) drops.
Use Diazepam (Redotex) Rectal Gel as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Diazepam (Redotex) Rectal Gel. Talk to your pharmacist if you have questions about this information.
- A health care provider will teach your caregiver how to use Diazepam (Redotex) Rectal Gel. Be sure your caregiver understands how to use Diazepam (Redotex) Rectal Gel. Contact your health care provider if you or your caregiver have any questions about using Diazepam (Redotex) Rectal Gel.
- To use Diazepam (Redotex) Rectal Gel, place the patient on their side where they cannot fall. Get the syringe. Push up with your thumb and remove the cap from the syringe. Be sure the seal pin is removed with the cap. Lubricate the rectal tip with the lubricating jelly provided.
- Turn the patient on their side facing you. Bend the upper leg forward and separate the buttocks to expose the rectum.
- Gently insert the syringe tip into the rectum. Slowly count to 3 while gently pushing the plunger in until it stops. Slowly count to 3 before removing the syringe from the rectum. Slowly count to 3 while holding the buttocks together to prevent leakage of the medicine.
- Keep the patient on their side facing you. Continue to observe the patient as directed by the patient's doctor.
- Do not reuse the syringe or other materials. Throw away all used materials in the trash can. Keep out of the reach of children and away from pets.
- Contact the patient's doctor at once if seizures continue for 15 minutes after using Diazepam (Redotex) Rectal Gel, unless the patient's doctor tells you otherwise.
- Contact the doctor at once if you are alarmed by the frequency or severity of the seizures, or the color or breathing of the patient.
- Contact the doctor at once if the seizures are different from the patient's usual seizure episodes or if the patient is having unusual or serious problems.
- Do NOT use Diazepam (Redotex) Rectal Gel more often than once every 5 days unless your doctor tells you otherwise.
- Do NOT use Diazepam (Redotex) Rectal Gel more often than 5 times per month unless your doctor tells you otherwise.
- If you miss a dose of Diazepam (Redotex) Rectal Gel, contact your doctor right away.
Ask your health care provider any questions you may have about how to use Diazepam (Redotex) Rectal Gel.
Use Liothyronine (Redotex) tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Liothyronine (Redotex) tablets by mouth with or without food.
- Liothyronine (Redotex) tablets works best if it is taken at the same time each day.
- Take Liothyronine (Redotex) tablets at least 4 hours apart from calcium salts (eg, calcium carbonate), cholestyramine, or sucralfate.
- Continuous use of Liothyronine (Redotex) tablets for a few weeks may be necessary to relieve symptoms of your condition.
- If you miss a dose of Liothyronine (Redotex) tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Liothyronine (Redotex) tablets.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Use: Labeled Indications
Antidote: Antidote for anticholinesterase poisoning (carbamate insecticides, nerve agents, organophosphate insecticides); antidote for muscarine-containing mushroom poisoning.
Adjuvant use with anticholinesterases (eg, edrophonium, neostigmine) to decrease their adverse effects during reversal of neuromuscular blockade.
Cardiovascular conditions: Treatment of symptomatic sinus bradycardia, atrioventricular (AV) nodal block.
Note: Likely not effective for type II second-degree or third-degree AV block (AHA [Hazinski 2015]). Use is no longer recommended in the management of asystole or pulseless electrical activity (PEA) (ACLS 2010).
Respiratory tract: Preoperative/preanesthetic medication to inhibit salivation and secretions.
Off Label Uses
Rapid sequence intubation (premedication)
Clinical experience suggests the utility of Atropine (Redotex) in adults who are at risk of developing bradycardia during rapid sequence intubation, such as those receiving conduction-altering drugs (eg, beta-blockers).
Based on the American Heart Association 2015 Handbook of Emergency Cardiovascular Care for Healthcare Providers, the use of Atropine (Redotex) is effective and recommended as a premedication to prevent bradycardia in adults undergoing rapid sequence intubation.
Based on the American Society of Nuclear Cardiology, Atropine (Redotex) may be administered as an adjunctive agent to increase heart rate in patients who do not achieve target heart rate with dobutamine alone.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Diazepam (Redotex) is used to treat anxiety, muscle spasms, and alcohol withdrawal. The injection form is used when prompt relief is desired or when the medication cannot be taken by mouth.
This medication is also used for the short-term treatment of serious seizures that do not stop (status epilepticus). It is not for ongoing daily use to prevent seizures.
Diazepam (Redotex) is also used before a surgery or procedure to cause drowsiness, decrease anxiety, and to help the patient forget what happened during the surgery/procedure.
This medication works by calming the brain and nerves. Diazepam (Redotex) belongs to a class of drugs known as benzodiazepines.
How to use Diazepam (Redotex) injection
This medication is given by injection into a vein or deep into a muscle as directed by your doctor. You should be closely monitored for several hours after receiving this medication.
If you are using this medication at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.
The dosage is based on your medical condition, age, and response to treatment. Giving the medication too fast into a vein can cause serious side effects. If giving this medication into a vein, inject it slowly into a large vein. Do not inject this medication into an artery or into the skin.
If you suddenly stop using this medication, you may have withdrawal symptoms (such as shaking, abdominal/muscle cramps, vomiting, sweating, anxiety, restlessness, seizures). To help prevent withdrawal, your doctor may lower your dose slowly. Withdrawal is more likely if you have used Diazepam (Redotex) for a long time or in high doses. Tell your doctor or pharmacist right away if you have withdrawal.
When this medication is used for a long time, it may not work as well. Talk with your doctor if this medication stops working well.
Along with its benefits, this medication may rarely cause abnormal drug-seeking behavior (addiction). This risk may be increased if you have abused alcohol or drugs in the past. Use this medication exactly as prescribed to lessen the risk of addiction.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Use: Labeled Indications
Thyroid disorders:
Oral: Replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism; adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer; a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.
Limitations of use: Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients; not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
Myxedema coma/precoma: IV: Treatment of myxedema coma/precoma
Note: May be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.
Off Label Uses
Antidepressant augmentation
Augmentation for treatment resistant depression: Data from a meta-analysis supports the use of Liothyronine (Redotex) in depression refractory to tricyclic antidepressants. Additional data may be necessary to further define the role of Liothyronine (Redotex) in this setting.
See also:
What other drugs will affect Atropine (Redotex)?
Atropine (Redotex) may cause increased anticholinergic activity when administered concomitantly with other anticholinergic drugs eg, phenothiazines, antispasmodics, antiparkinsonian drugs, antiarrhythmics with anticholinergic activity eg, disopyramide and quinidine, some antihistamines, tricyclic antidepressants or butyrophenones.
The absorption of other drugs may be affected by the reduction in gastric motility caused by Atropine (Redotex).
Atropine (Redotex) antagonises the actions of a number of compounds including synthetic choline esters eg, bethanechol and carbachol, anticholinesterase drugs eg, physostigmine, neostigmine and pyridostigmine and cholinomimetic alkaloids eg, pilocarpine.
Ketoconazole: Anticholinergics may increase gastrointestinal pH, possibly resulting in a marked reduction in ketoconazole absorption during concurrent use with anticholinergics; patients should be advised to take these medications at least 2 hrs after ketoconazole.
Cisapride and Metoclopramide: Concurrent use with anticholinergics may antagonise the gastrointestinal motility of cisapride and metoclopramide.
Opioid (Narcotic) Analgesics: Concurrent use with anticholinergics may result in increased risk of severe constipation, which may lead to paralytic ileus and/or urinary retention.
Haloperidol: Antipsychotic effectiveness of haloperidol may be decreased in schizophrenic patients.
Cholinesterase Inhibitors: In view of the pharmacodynamic effects of Atropine (Redotex), Atropine (Redotex) may interfere with the activity of cholinesterase inhibitors eg, rivastigmine, donepezil.
Incompatibilities: Atropine (Redotex) Injection Pfizer has been shown to be incompatible with solutions containing adrenaline HCl, amylobarbitone sodium, pentobarbitone sodium, promazine HCl, ampicillin sodium, chloramphenicol sodium succinate, chlortetracycline HCl, heparin sodium, metaraminol tartrate, methicillin sodium, nitrofurantoin, novobiocin, oxacillin sodium, sodium bicarbonate, sulfadiazine sodium, sulfafurazole diethanolamine, tetracycline HCl, thiopentone sodium, vitamin B complex with ascorbic acid and warfarin sodium. This list is not exhaustive.
Reduced effect of guanethidine. Increased risk of arrhythmia in patients treated with digitalis due to its sympathomimetic effects. Increased risk of arrhythmia with choroform, cyclopropane, halothane or other halogenated anesthetics. The effect of Cathine (Redotex) may be reduced/enhanced by tricyclic anti-depressants.
Potentially Fatal: Cathine (Redotex) should not be used in patients treated with a MAOI or within 14 days of stopping MAOI as hypertensive crisis may occur if used.
See also:
What other drugs will affect Diazepam (Redotex)?
If Diazepam (Redotex) rectal gel is to be combined with other psychotropic agents or other CNS depressants, careful consideration should be given to the pharmacology of the agents to be employed particularly with known compounds which may potentiate the action of Diazepam (Redotex), such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants.
The clearance of Diazepam (Redotex) and certain other benzodiazepines can be delayed in association with cimetidine administration. The clinical significance of this is unclear.
Valproate may potentiate the CNS-depressant effects of Diazepam (Redotex).
There have been no clinical studies or reports in literature to evaluate the interaction of rectally administered Diazepam (Redotex) with other drugs. As with all drugs, the potential for interaction by a variety of mechanisms is a possibility.
Effect of Other Drugs on Diazepam (Redotex) Metabolism: In vitro studies using human liver preparations suggest that CYP2C19 and CYP3A4 are the principal isozymes involved in the initial oxidative metabolism of Diazepam (Redotex). Therefore, potential interactions may occur when Diazepam (Redotex) is given concurrently with agents that affect CYP2C19 and CYP3A4 activity. Potential inhibitors of CYP2C19 (e.g., cimetidine, quinidine, and tranylcypromine) and CYP3A4 (e.g., ketoconazole, troleandomycin, and clotrimazole) could decrease the rate of Diazepam (Redotex) elimination, while inducers of CYP2C19 (e.g., rifampin) and CYP3A4 (e.g., carbamazepine, phenytoin, dexamethasone and phenobarbital) could increase the rate of elimination of Diazepam (Redotex).
Effect of Diazepam (Redotex) on the Metabolism of Other Drugs : There are no reports as to which isozymes could be inhibited or induced by Diazepam (Redotex). But, based on the fact that Diazepam (Redotex) is a substrate for CYP2C19 and CYP3A4, it is possible that Diazepam (Redotex) may interfere with the metabolism of drugs which are substrates for CYP2C19, (e.g. omeprazole, propranolol, and imipramine) and CYP3A4 (e.g. cyclosporine, paclitaxel, terfenadine, theophylline, and warfarin) leading to a potential drug-drug interaction.
See also:
What other drugs will affect Liothyronine (Redotex)?
Oral Anticoagulants
Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy.
Insulin Or
Oral Hypoglycemics
Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.
Estrogen,
Oral Contraceptives
Estrogens tend to increase serum thyroxine-binding globulin (TBG). In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements. However, if the patient's thyroid gland has sufficient function, the decreased free thyroxine will result in a compensatory increase in thyroxine output by the thyroid. Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
Tricyclic Antidepressants
Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity; transient cardiac arrhythmias have been observed. Thyroid hormone activity may also be enhanced.
Digitalis
Thyroid preparations may potentiate the toxic effects of digitalis. Thyroid hormonal replacement increases metabolic rate, which requires an increase in digitalis dosage.
Ketamine
When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia. Use with caution and be prepared to treat hypertension, if necessary.
Vasopressors
Thyroid hormones increase the adrenergic effect of catecholamines such as epinephrine and norepinephrine. Therefore, use of vasopressors in patients receiving thyroid hormone preparations may increase the risk of precipitating coronary insufficiency, especially in patients with coronary artery disease. Therefore, use caution when administering vasopressors with Liothyronine (Redotex) (T values. In such cases, the unbound (free) hormone should be measured. Pregnancy, estrogens and estrogen-containing oral contraceptives increase TBG concentrations. TBG may also be increased during infectious hepatitis. Decreases in TBG concentrations are observed in nephrosis, acromegaly and after androgen or corticosteroid therapy. Familial hyper- or hypothyroxine-binding globulinemias have been described. The incidence of TBG deficiency approximates 1 in 9000. The binding of thyroxine by thyroxine-binding prealbumin (TBPA) is inhibited by salicylates.
See also:
What are the possible side effects of Atropine (Redotex)?
Mild to moderate pain may be experienced at the site of injection.
The major and most common side effects of Atropine (Redotex) can be attributed to its antimuscarinic action. These include dryness of the mouth, blurred vision, photophobia, confusion, headache, dizziness, tachycardia, palpitations, flushing, urinary hesitance or retention, constipation, abdominal distention, nausea, vomiting, loss of libido and impotency. Anhidrosis may produce heat intolerance and impairment of temperature regulation especially in a hot environment. Larger or toxic doses may produce such central effects as restlessness, tremor, fatigue, locomotor difficulties, delirium, followed by hallucinations, depression and ultimately, medullary paralysis and death. Large doses can also lead to circulatory collapse. In such cases, blood pressure declines and death due to respiratory failure may ensue following paralysis and coma. Hypersensitivity reactions will occasionally occur with Atropine (Redotex): these are usually seen as skin rashes, on occasion progressing to exfoliation. Adverse events seen in pediatrics are similar to those that occur in adult patients although central nervous system complaints are often seen earlier and at lower doses.
When Atropine (Redotex) and pralidoxime are used together, the signs of atropinization may occur earlier than might be expected than when Atropine (Redotex) is used alone. This is especially true if the total dose of Atropine (Redotex) has been large and the administration of pralidoxime has been delayed. Excitement and manic behavior immediately following recovery of consciousness have been reported in several cases. However, similar behavior has occurred in cases of organophosphate poisoning that were not treated with pralidoxime.
Amitai et el (JAMA 1990) evaluated the safety of Atropine (Redotex)® (Atropine (Redotex)) 0.5 mg, 1 mg and 2 mg in a case series of 240 children who received Atropine (Redotex)® (Atropine (Redotex)) inappropriately (i.e., no nerve agent exposure) during the 1990 Gulf War Period. Overall, severity of atropinization followed a nonlinear correlation with dose. Estimated doses up to 0.045 mg/kg produced no signs of atropinization. Estimated doses between 0.045 mg/kg to 0.175 mg/kg and even greater than 0.175 mg/kg were associated with mild and severe effects respectively. Actual dosage received by children may have been considerably lower than estimated since incomplete injection in many cases was suspected. Regardless, adverse events reported were generally mild and self-limited. Few children required hospitalization. Adverse reactions reported were dilated pupils (43%), tachycardia (39%), dry membranes (35%), flushed skin (20%), temperature 37.8° C or 100° F (4%) and neurologic abnormalities (5%). There was also local pain and swelling. In 91 children with ECGs, no abnormalities were noted other than sinus tachycardia; 22 children had severe tachycardia of 160-190 bpm. Neurologic abnormalities consisted of irritability, agitation, confusion, lethargy, and ataxia.
The following adverse reactions were reported in published literature for Atropine (Redotex) in both adults and children:
Cardiovascular: Sinus tachycardia, supraventricular tachycardia, junctional tachycardia, ventricular tachycardia, bradycardia, palpitations, ventricular arrhythmia, ventricular flutter, ventricular fibrillation, atrial arrhythmia, atrial fibrillation, atrial ectopic beats, ventricular premature contractions, bigeminal beats, trigeminal beats, nodal extrasystole, ventricular extrasystole, supraventricular extrasystole, asystole, cardiac syncope, prolongation of sinus node recovery time, cardiac dilation, left ventricular failure, myocardial infarction, intermittent nodal rhythm (no P wave), prolonged P wave, shortened PR segment, R on T phenomenon, shortened RT duration, widening and flattening of QRS complex, prolonged QT interval, flattening of T wave, repolarization abnormalities, altered ST-T waves, retrograde conduction, transient AV dissociation, increased blood pressure, decreased blood pressure, labile blood pressure, weak or impalpable peripheral pulses.
Eye: Mydriasis, blurred vision, pupils poorly reactive to light, photophobia, decreased contrast sensitivity, decreased visual acuity, decreased accommodation, cycloplegia, strabismus, heterophoria, cyclophoria, acute angle closure glaucoma, conjunctivitis, keratoconjunctivitis sicca, blindness, tearing, dry eyes/dry conjunctiva, irritated eyes, crusting of eyelid, blepharitis.
Gastrointestinal: Nausea, abdominal pain, paralytic ileus, decreased bowel sounds, distended abdomen, vomiting, delayed gastric emptying, decreased food absorption, dysphagia.
General:Hyperpyrexia, lethargy, somnolence, chest pain, excessive thirst, weakness, syncope, insomnia, tongue chewing, dehydration, feeling hot, injection site reaction.
Immunologic: Anaphylactic reaction.
Special Investigations: Leukocytosis, hyponatremia, elevated BUN, elevated hemoglobin, elevated erythrocytes, low hemoglobin, hypoglycemia, hyperglycemia, hypokalemia, increase in photic stimulation on EEG, signs of drowsiness on EEG, runs of alpha waves on EEG, alpha waves (EEG) blocked upon opening eyes.
Metabolic: Failure to feed.
Central Nervous System: Ataxia, hallucinations (visual or aural), seizures (generally tonic clonic), abnormal movements, coma, confusion, stupor, dizziness, amnesia, headache, diminished tendon reflexes, hyperreflexia, muscle twitching, opisthotnos, Babinski's reflex/Chaddock's reflex, hypertonia, dysmetria, muscle clonus, sensation of intoxication, difficulty concentrating, vertigo, dysarthria.
Psychiatric: Agitation, restlessness, delirium, paranoia, anxiety, mental disorders, mania, withdrawn behavior, behavior changes.
Genitourinary: Difficulty in micturation, urine urgency distended urinary bladder, urine retention, bed-wetting.
Pulmonary: Tachypnea, slow respirations, shallow respirations, breathing difficulty, labored respirations, inspiratory stridor, laryngitis, laryngospasm, pulmonary edema, respiratory failure, subcostal recession.
Dermatologic: Dry mucous membranes, dry warm skin, flushed skin, oral lesions, dermatitis, petechiae rash, macular rash papular rash, maculopapular rash, scarlatiniform rash, erythematous rash, sweating/moist skin, cold skin, cyanosed skin, salivation.
Drug Abuse And Dependence
Atropine (Redotex) possesses no known potential for dependence.
In large doses giddiness, headache, nausea, vomiting, sweating, dryness of the mouth and thirst, tachycardia, precordial pain, palpitation, difficulty in micturition, muscular weakness and tremors, anxiety, restlessness and insomnia may occur.
Some patients may exhibit these symptoms with the therapeutic dose. These agents may produce psychotic reactions, agitation and excitability. They should be used with caution in patients with history of psychiatric illness. Prolonged administration has no cumulative effect but tolerance with dependence has been reported.
Use with caution in patients receiving chloroform, cyclopropane, halothane or other halogenated anaesthetics.
this medicine may diminish the effects of guanethidine and may increase the possibility of arrythmias in digitalised patients. this medicine should be taken with caution by patients with organic heart disease, cardiac decompensation or angina of effort in patients receiving digitalis.
The effects of this medicine may be diminished or enhanced by tricyclic anti-depressants.
In patients with prostatic enlargement, it may increase difficulty with micturition.
The preparation should not be taken late in the afternoon because of its stimulant effect on the central nervous system.
These agents are liable to be abused. They should be used with extreme caution in patients with a history of drug or alcohol abuse and in patients with personality disorders. There is a lack of evidence for efficacy in the long-term management of obesity.
Systolic and diastolic blood pressure may be increased, especially with high doses and anginal pain or cardiac arrhythmia’s may occur.
These agents should be administered cautiously to patients suffering from cardiovascular disease (especially coronary insufficiency), hypertension, thyrotoxicosis and narrow angle glaucoma.
See also:
What are the possible side effects of Diazepam (Redotex)?
Diazepam (Redotex) rectal gel adverse event data were collected from double-blind, placebo-controlled studies and open-label studies. The majority of adverse events were mild to moderate in severity and transient in nature.
Two patients who received Diazepam (Redotex) rectal gel died seven to 15 weeks following treatment; neither of these deaths was deemed related to Diazepam (Redotex) rectal gel.
The most frequent adverse event reported to be related to Diazepam (Redotex) rectal gel in the two double-blind, placebo-controlled studies was somnolence (23%). Less frequent adverse events were dizziness, headache, pain, abdominal pain, nervousness, vasodilatation, diarrhea, ataxia, euphoria, incoordination, asthma, rhinitis, and rash, which occurred in approximately 2-5% of patients.
Approximately 1.4% of the 573 patients who received Diazepam (Redotex) rectal gel in clinical trials of epilepsy discontinued treatment because of an adverse event. The adverse event most frequently associated with discontinuation (occurring in three patients) was somnolence. Other adverse events most commonly associated with discontinuation and occurring in two patients were hypoventilation and rash. Adverse events occurring in one patient were asthenia, hyperkinesia, incoordination, vasodilatation and urticaria. These events were judged to be related to Diazepam (Redotex) rectal gel.
In the two domestic double-blind, placebo-controlled, parallel-group studies, the proportion of patients who discontinued treatment because of adverse events was 2% for the group treated with Diazepam (Redotex) rectal gel, versus 2% for the placebo group. In the Diazepam (Redotex) rectal gel group, the adverse events considered the primary reason for discontinuation were different in the two patients who discontinued treatment; one discontinued due to rash and one discontinued due to lethargy. The primary reason for discontinuation in the patients treated with placebo was lack of effect.
Adverse Event Incidence In Controlled Clinical Trials
Table 1 lists treatment-emergent signs and symptoms that occurred in > 1% of patients enrolled in parallel-group, placebo-controlled trials and were numerically more common in the Diazepam (Redotex) rectal gel group. Adverse events were usually mild or moderate in intensity.
The prescriber should be aware that these figures, obtained when Diazepam (Redotex) rectal gel was added to concurrent antiepileptic drug therapy, cannot be used to predict the frequency of adverse events in the course of usual medical practice when patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescribing physician with one basis to estimate the relative contribution of drug and non-drug factors to the adverse event incidences in the population studied.
TABLE 1: Treatment-Emergent Signs And Symptoms That Occurred In > 1% Of Patients Enrolled In Parallel-Group, Placebo-Controlled Trials And Were Numerically More Common In The Diazepam (Redotex) Rectal Gel Group
Body System | COSTART Term | Diazepam (Redotex) Rectal Gel N = 101 % | Placebo N = 104 % |
Body As A Whole | Headache | 5% | 4% |
Cardiovascular | Vasodilatation | 2% | 0% |
Digestive | Diarrhea | 4% | < 1% |
Nervous | Ataxia | 3% | < 1% |
Dizziness | 3% | 2% | |
Euphoria | 3% | 0% | |
Incoordination | 3% | 0% | |
Somnolence | 23% | 8% | |
Respiratory | Asthma | 2% | 0% |
Skin and Appendages | Rash | 3% | 0% |
Other events reported by 1% or more of patients treated in controlled trials but equally or more frequent in the placebo group than in the Diazepam (Redotex) rectal gel group were abdominal pain, pain, nervousness, and rhinitis. Other events reported by fewer than 1% of patients were infection, anorexia, vomiting, anemia, lymphadenopathy, grand mal convulsion, hyperkinesia, cough increased, pruritus, sweating, mydriasis, and urinary tract infection.
The pattern of adverse events was similar for different age, race and gender groups.
Other Adverse Events Observed During All Clinical Trials
Diazepam (Redotex) rectal gel has been administered to 573 patients with epilepsy during all clinical trials, only some of which were placebo-controlled. During these trials, all adverse events were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using modified COSTART dictionary terminology. These categories are used in the listing below. All of the events listed below occurred in at least 1% of the 573 individuals exposed to Diazepam (Redotex) rectal gel.
All reported events are included except those already listed above, events unlikely to be drug-related, and those too general to be informative. Events are included without regard to determination of a causal relationship to Diazepam (Redotex).
BODY AS A WHOLE: Asthenia
CARDIOVASCULAR: Hypotension, vasodilatation
NERVOUS: Agitation, confusion, convulsion, dysarthria, emotional lability, speech disorder, thinking abnormal, vertigo
RESPIRATORY: Hiccup
The following infrequent adverse events were not seen with Diazepam (Redotex) rectal gel but have been reported previously with Diazepam (Redotex) use: depression, slurred speech, syncope, constipation, changes in libido, urinary retention, bradycardia, cardiovascular collapse, nystagmus, urticaria, neutropenia and jaundice. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations, increased muscle spasticity, insomnia, rage, sleep disturbances and stimulation have been reported with Diazepam (Redotex); should these occur, use of Diazepam (Redotex) rectal gel should be discontinued.
Drug Abuse And Dependence
Diazepam (Redotex) is a Schedule IV controlled substance and can produce drug dependence. It is recommended that patients be treated with Diazepam (Redotex) rectal gel no more frequently than every five days and no more than five times per month.
Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving Diazepam (Redotex) or other psychotropic agents because of the predisposition of such patients to habituation and dependence.
Abrupt discontinuation of Diazepam (Redotex) following chronic regular use has resulted in withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating). The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuation of benzodiazepines taken continuously at therapeutic levels for several months.
See also:
What are the possible side effects of Liothyronine (Redotex)?
Applies to Liothyronine (Redotex): oral tablet
Other dosage forms:
- intravenous injectable, intravenous solution
In addition to its needed effects, some unwanted effects may be caused by Liothyronine (Redotex) (the active ingredient contained in Liothyronine (Redotex)). In the event that any of these side effects do occur, they may require medical attention.
If any of the following symptoms of overdose occur while taking Liothyronine (Redotex), get emergency help immediately:
- Arm, back or jaw pain
- changes in appetite
- changes in menstrual periods
- chest pain or discomfort
- chest tightness or heaviness
- cold clammy skin
- confusion
- decreased urine output
- diarrhea
- dilated neck veins
- dizziness
- extreme fatigue
- fainting
- fast, slow, pounding, or irregular heartbeat or pulse
- fever
- hand tremors
- headache
- increased bowel movements
- irregular breathing
- irritability
- leg cramps
- lightheadedness
- menstrual changes
- nausea
- nervousness
- sensitivity to heat
- shortness of breath
- sweating
- swelling of face, fingers, feet, or lower legs
- troubled breathing
- trouble sleeping
- vomiting
- weak pulse
- weight gain
- weight loss
- wheezing
Atropine (Redotex) Injection Pfizer also contains sodium chloride and water for injections.
Atropine (Redotex) sulfate is bis (1R, 3r, 5S)-3-[(RS)-(3-hydroxy-2-phenylpropionyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane sulfate. It appears as colourless crystals or a white, crystalline powder. It is very soluble in water, freely soluble in alcohol and practically insoluble in ether. It has a molecular formula of (C17H23NO3)2,H2SO4,H2O and a molecular weight of 695.
A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Cathine (Redotex) has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Cathine (Redotex) is a controlled substance in the U.S.
Each tablet contains Diazepam (Redotex) 2 mg, 5 mg and 10 mg, respectively. Each ampoule contain Diazepam (Redotex) 10 mg/2 mL. It also contains the following excipients: Tablets: Lactose. Ampoules: Benzyl alcohol.
The L-triiodothyronine (T3, Liothyronine (Redotex)) thyroid hormone is normally synthesized and secreted by the thyroid gland in much smaller quantities than L-tetraiodothyronine (T4, levothyroxine, L-thyroxine). Most T3 is derived from peripheral monodeiodination of T4 at the 5 position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. [PubChem]